REG - Futura Medical PLC - Result of AGM

Futura MedicalAnnouncement

20/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250620:nRST6681Na&default-theme=true

RNS Number : 6681N  Futura Medical PLC  20 June 2025

20 June 2025

 

Futura Medical plc

("Futura" or the "Company")

Notice of Results and Investor Presentation

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, today announces that
at its Annual General Meeting, held yesterday at 10:00am BST, the shareholders
duly passed all resolutions.

 

The total number of votes received on each resolution were as follows:

 

                                                                                                      Voting For                                                    Voting Against
                     Number of votes(i)                                                               %                              Number of votes                %                                Total Votes                      % ISC        Votes withheld(ii)
 Resolution 1        To receive and adopt the annual report and accounts for the financial year       146,144,976                    48.12                          721,656                          0.24                             146,866,632  48.36       261,557
                     ended 31 December 2024

 Resolution 2        That Harmesh Suniara be and is hereby appointed as a Director of the Company.    145,681,511                    47.97                          1,136,919                        0.37                             146,818,430  48.34       309,759

 Resolution 3        To re-elect Jeff Needham as a Director of the Company, who retires by rotation   145,170,141                    47.80                          1,277,566                        0.42                             146,447,707  48.22       680,482
                     in accordance with the Company's articles of association.

 Resolution 4        To re-elect Andrew Unitt as a Director of the Company, who retires by rotation   145,170,141                    47.80                          1,277,566                        0.42                             146,447,707  48.22       680,482
                     in accordance with the Company's articles of association.

 Resolution 5        To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office     146,113,545                    48.12                          851,161                          0.28                             146,964,706  48.40       163,483
                     until the conclusion of the next annual general meeting of the Company.

 Resolution 6        To authorise the Directors to determine the remuneration of Grant Thornton UK    145,401,415                    47.88                          1,080,802                        0.36                             146,482,217  48.24       645,972
                     LLP as auditor of the Company.

 Resolution 7        That the Directors be and are generally and unconditionally authorised for the   144,897,392                    47.71                          1,986,162                        0.65                             146,883,554  48.36       244,635
                     purposes of section 551 Companies Act 2006 to exercise all the powers of the

                     Company to allot shares in the Company and to grant rights to subscribe for or
                     to convert any security into shares in the Company
 Resolution 8 (iii)  Disapplication of pre-emption rights in respect of an additional 20% of the      144,632,144                    47.62                          2,041,210                        0.67                             146,673,354  48.29       454,835
                     company issued share capital

 Resolution 9 (iii)  To resolve that, subject to the passing of Resolution 8 set out above, the       145,010,004                    47.75                          1,860,610                        0.61                             146,870,614  48.36       257,575
                     Directors be authorised in addition to any authority granted under Resolution

                     8 to allot equity securities for cash under the authority given by that
                     resolution as if section 561 of the CA 2006 did not apply to any such
                     allotment or sale

 

i       Where shareholders appointed the Chairman as their proxy with
discretion as to voting, their votes were cast in favour of the resolution

ii      A vote withheld is not a vote in law and is not counted towards
the votes cast "For" or "Against" a resolution

iii     ⁱSpecial Resolution (75% majority required)

 

The total voting rights of the Company as at 10:00 am on 17 June 2025 (the
time by which shareholders wanting to vote at the AGM were required to be
entered on the register) was 303,703,568 ordinary shares of 0.2 pence each.
The Company does not hold any shares in treasury.

 

Contacts:

 Futura Medical plc             James Barder                                            investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                Chief Executive Officer

                                                       +44 (0)1483 685 670
                                Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                Finance Director and COO

 Panmure Liberum                Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser              Rupert Dearden (Corporate Broking)

 and Broker

 Alma Strategic Communications  Rebecca Sanders-Hewett                                  +44 (0)20 3405 0205

                                Sam Modlin                                              futura@almastrategic.com

                                Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and products WSD4000 and
Eroxon(®) Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of Erectile Dysfunction ("ED"). The highly differentiated
product, which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten minutes, addresses significant
unmet needs in the ED market. Eroxon(®) has been nominated for a number of
healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGUKURRVNUNAUR